In CRC and PDAC, three hotspots for KRAS missense mutations (G12, G13, and Q61) lead to KRAS oncoproteins sustaining proliferative signaling, mainly through the MAPK and PI3K‐AKT signaling pathways [8]. Here, KRAS is linked to colorectal carcinoma.